Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma

J Manag Care Spec Pharm. 2018 Jul;24(7):711-712. doi: 10.18553/jmcp.2018.24.7.711.

Abstract

Ailawadhi reports research support from Pharmacyclics and consulting relationships with Takeda, Amgen, and Celgene. Jakubowiak reports consulting and advisory board relationships with AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDX, and Takeda. Panjabi, Campioni, and Majer are employees of and stockholders in Amgen.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Cost-Benefit Analysis
  • Humans
  • Multiple Myeloma*
  • United States